MBX Biosciences Inc.
Organization details
- Legal name
- MBX Biosciences Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Carmel
- Headquarters state / province
- Indiana
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MBX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001776111
Board of directors
- Since 2024
- Since 2024
-
James M. Cornelius · DirectorSince 2024
-
Laurie Stelzer · DirectorSince 2026
-
Ora H. Pescovitz · DirectorSince 2024
-
P. Kent Hawryluk · Director · President & CEOSince 2024
-
Patrick J. Heron · DirectorSince 2024
-
Peter Radovich · DirectorSince 2026
-
Steven L. Hoerter · Director · President and CEOSince 2025
-
Steven Ryder · DirectorSince 2024
-
Tiba Aynechi · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
80.8%
-
88.4%
Board connections
6 of this board's directors also sit on 21 other boards. 21 are in the same sector.
-
ADARx Pharmaceuticals Inc. Same sectorvia Carl L. Gordon
-
Adicet Bio Inc. Same sectorvia Carl L. Gordon
-
Arcutis Biotherapeutics Inc. Same sectorvia Patrick J. Heron
-
ArriVent BioPharma Inc. Same sectorvia Carl L. Gordon
-
BlossomHill Therapeutics Inc. Same sectorvia Carl L. Gordon
-
C4 Therapeutics Inc. Same sectorvia Steven L. Hoerter
-
Compass Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Electra Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Keros Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Mirum Pharmaceuticals Inc. Same sectorvia Patrick J. Heron
-
OnKure Therapeutics Inc. Same sectorvia Edward T. Mathers
-
Oric Pharmaceuticals Inc. Same sectorvia Steven L. Hoerter
-
PMV Pharmaceuticals Inc. Same sectorvia Laurie Stelzer
-
Rhythm Pharmaceuticals Inc. Same sectorvia Edward T. Mathers
-
Scribe Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Senti Biosciences Holdings Inc. Same sectorvia Edward T. Mathers
-
Sionna Therapeutics Inc. Same sectorvia Laurie Stelzer
-
Spruce Biosciences Inc. Same sectorvia Tiba Aynechi
-
Spyre Therapeutics Inc. Same sectorvia Laurie Stelzer
-
Trevi Therapeutics Inc. Same sectorvia Edward T. Mathers
-
Yarrow Bioscience Inc. Same sectorvia Steven L. Hoerter
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $525,585
- 1 purchase by 1 insider
- Sold, last 12 months
- $2,754,731
- 6 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −373 | $53.96 | $20,127 |
| Aug 4, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −370 | $65.77 | $24,335 |
| Aug 3, 2026 | Steven L. Hoerter Director, Officer (President and CEO) | Grant or award | +71,000 | — | — |
| Aug 3, 2026 | John W. Smither Officer (Chief Financial Officer) | Grant or award | +28,000 | — | — |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Option exercise | +55,000 | $10.46 | $575,300 |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −55,000 | $38.38 | $2,110,900 |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Option exercise | +15,003 | $16.00 | $240,048 |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −15,003 | $38.30 | $574,615 |
| May 6, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −231 | $29.54 | $6,824 |
| May 6, 2026 | P. Kent Hawryluk Director, Officer (President & CEO) | Open-market sale | −607 | $29.54 | $17,931 |
| May 1, 2026 | Steven L. Hoerter Director | Grant or award | +11,938 | — | — |
| Mar 13, 2026 | P. Kent Hawryluk Director, Officer (President & CEO) | Open-market purchase | +18,500 | $28.41 | $525,585 |
| Feb 26, 2026 | P. Kent Hawryluk Director, Officer (President & CEO) | Option exercise | +28,768 | $16.00 | $460,288 |
| Feb 2, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Grant or award | +15,000 | — | — |
| Feb 2, 2026 | Bartram Richard Officer (Chief Financial Officer) | Grant or award | +15,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about MBX Biosciences Inc.
Who is the CEO of MBX Biosciences Inc.?
P. Kent Hawryluk has been MBX Biosciences Inc.'s President & CEO since September 2024.
How many directors are on MBX Biosciences Inc.'s board?
MBX Biosciences Inc.'s board has 11 directors: Carl L. Gordon, Edward T. Mathers, James M. Cornelius, Laurie Stelzer, Ora H. Pescovitz, P. Kent Hawryluk, Patrick J. Heron, Peter Radovich, Steven L. Hoerter, Steven Ryder and 1 other.
Are MBX Biosciences Inc. insiders buying or selling shares?
Over the last 12 months, MBX Biosciences Inc. insiders bought $525,585 of shares in 1 purchase and sold $2.8 million of shares in 6 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="mbx-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.